Résumé
Objective To investigate the effect of budesonide nasal spray and ebastine combined with Xinqin granule on symptom improvement and serum T cell subsets and vascular cell adhesion molecule －1 ( VCAM －1) levels in patients with allergic rhinitis.Methods From February 2015 to April 2017,107 cases of allergic rhinitis in Yuncheng Central Hospital were divided into two groups according to the different ways of treatment .Fifty －three cases in the control group were treated with budesonide nasal spray and ebastine ,54 cases in the study group were treated with Xinqin granule based on the control group.The improvement of nasal congestion ,sneezing,runny nose, nasal itching symptom score and serum VCAM －1,T cell subsets (CD+3 ,CD+4 ,CD+19 ) levels of the two groups were analyzed and compared before treatment and after half a month of the treatment .The clinical effect and incidence of adverse reactions were compared between the two groups.Results After treatment for half a month , the nasal congestion,sneezing,runny nose,nasal itching symptom scores of the study group were lower than those of the control group(all P＜0.05).The clinical effect of the study group [87.04%(47／54)] was higher than that of the control group[67.92%(31／53),χ2 ＝2.970,P＜0.05].After treatment for half a month,the serum VCAM－1,CD+3 ,CD+4 and CD+19 levels in the study group were better than those in the control group [(572.26 ±120.67)ng／L vs.(864.87 ± 238.56)ng／L,(68.69 ±3.31)% vs.(72.08 ±4.29)%,(39.79 ±3.28)% vs.(44.61 ±4.78)%,(10.79 ± 1.64)%vs.(13.61 ±2.18)%] ( all P＜0.05).The incidence rate of adverse reactions in the study group was 11.11%(6／54).which in the control group was 5.66%(3／53),the difference was not statistically significant (χ2 ＝0.445,P＝0.504).Conclusion Budesonide nasal spray and ebastine combined with Xinqin granule in the treatment of patients with allergic rhinitis has significant effect.It can significantly improve the levels of serum VCAM －1 and T cell subsets with high security.
Résumé
Objective@#To investigate the effect of budesonide nasal spray and ebastine combined with Xinqin granule on symptom improvement and serum T cell subsets and vascular cell adhesion molecule-1(VCAM-1) levels in patients with allergic rhinitis.@*Methods@#From February 2015 to April 2017, 107 cases of allergic rhinitis in Yuncheng Central Hospital were divided into two groups according to the different ways of treatment.Fifty-three cases in the control group were treated with budesonide nasal spray and ebastine, 54 cases in the study group were treated with Xinqin granule based on the control group.The improvement of nasal congestion, sneezing, runny nose, nasal itching symptom score and serum VCAM-1, T cell subsets (CD3＋, CD4＋, CD19＋) levels of the two groups were analyzed and compared before treatment and after half a month of the treatment.The clinical effect and incidence of adverse reactions were compared between the two groups.@*Results@#After treatment for half a month, the nasal congestion, sneezing, runny nose, nasal itching symptom scores of the study group were lower than those of the control group(all P<0.05). The clinical effect of the study group[87.04%(47/54)] was higher than that of the control group[67.92%(31/53), χ2=2.970, P<0.05]. After treatment for half a month, the serum VCAM-1, CD3＋, CD4＋ and CD19＋ levels in the study group were better than those in the control group[(572.26±120.67)ng/L vs.(864.87±238.56)ng/L, (68.69±3.31)% vs.(72.08±4.29)%, (39.79±3.28)% vs.(44.61±4.78)%, (10.79±1.64)% vs.(13.61±2.18)%](all P<0.05). The incidence rate of adverse reactions in the study group was 11.11%(6/54). which in the control group was 5.66%(3/53), the difference was not statistically significant (χ2=0.445, P=0.504).@*Conclusion@#Budesonide nasal spray and ebastine combined with Xinqin granule in the treatment of patients with allergic rhinitis has significant effect.It can significantly improve the levels of serum VCAM-1 and T cell subsets with high security.